Therapeutic Advances in Vaccines and Immunotherapy最新文献

{"title":"Vaccine hesitancy in Africa: causes and strategies to the rescue.","authors":"Abdullahi Tunde Aborode, Emmanuel Adebowale Fajemisin, Osmond C Ekwebelem, Christos Tsagkaris, Edeh Abigael Taiwo, Olivier Uwishema, Oluwasola Oluwabusayo Awoniyi, Shoaib Ahmad, Mohammad Yasir Essar, Irem Adanur, Ismaeel Yunusa","doi":"10.1177/25151355211047514","DOIUrl":"https://doi.org/10.1177/25151355211047514","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Dear Editor,","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211047514"},"PeriodicalIF":0.0,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/45/10.1177_25151355211047514.PMC8481750.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transdermal approaches to vaccinations in the COVID-19 pandemic era.","authors":"Michelle S Lee,&nbsp;Catherina X Pan,&nbsp;Vinod E Nambudiri","doi":"10.1177/25151355211039073","DOIUrl":"https://doi.org/10.1177/25151355211039073","url":null,"abstract":"<p><p>The COVID-19 pandemic has necessitated rapid vaccine development for the control of the disease. Most vaccinations, including those currently approved for COVID-19 are administered intramuscularly and subcutaneously using hypodermic needles. However, there are several disadvantages including pain and fear of needlesticks, the need for two doses, the need for trained health care professionals for vaccine administration, and barriers to global distribution given the need for cold supply chain. Recently, transdermal techniques have been under investigation for vaccines including COVID-19. Microneedle array technology utilizes multiple microscopic projections from a plate which delivers a vaccine in the form of a patch placed on the skin, allowing for painless antigen delivery with improved immune response. In this review, we discuss challenges of existing vaccines and review the literature on the science behind transdermal vaccines including microneedles, current evidence of application in infectious diseases including COVID-19, and considerations for implementation and global access.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211039073"},"PeriodicalIF":0.0,"publicationDate":"2021-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/75/10.1177_25151355211039073.PMC8384302.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39358949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of educational intervention on the best immunization practices among practicing health care professionals in a south Indian city.","authors":"Juny Sebastian,&nbsp;Gurumurthy Parthasarathi,&nbsp;Mandyam Dhati Ravi","doi":"10.1177/25151355211032590","DOIUrl":"https://doi.org/10.1177/25151355211032590","url":null,"abstract":"<p><strong>Background and aims: </strong>Maintaining the quality and safety of immunization is as important as the efficacy of vaccines in vaccine-preventable diseases (VPD) programs. The aim of this study was to determine the problems associated with different stages of vaccine use and to assess the outcome of an educational intervention on safety and quality use of vaccines among health care providers.</p><p><strong>Methods: </strong>A pilot prospective interventional study was conducted over a period of 2 years at 271 sites in Mysuru, India. The study population was health care professionals (HCPs) involved in immunization and a sample of parents (one per site). A validated questionnaire was used as a study tool. An educational intervention on best immunization practice was conducted for the enrolled HCPs and the impact of the educational intervention was assessed using the study tool after 3 weeks.</p><p><strong>Results: </strong>The total number of the study population was 594 (323 HCPs and 271 parents). Of these, 41.49% were working at community health care facility and 33.13% were enrolled from primary care centers. There were statistically significant improvements in post interventional assessment of all stages of the immunization process including storage (<i>p</i> -0.001), transportation (<i>p</i> -0.001), administration (<i>p</i> 0.001), monitoring and reporting of adverse events following immunization (AEFIs) (<i>p</i> -0.001), knowledge of AEFIs (<i>p</i> 0.001), and HCP-parent communication (<i>p</i> 0.001). AEFI reporting improved by 30% in the post education phase.</p><p><strong>Conclusion: </strong>Continuous education and motivation can result in positive behavioral changes on best immunization practices amongst HCPs involved in immunization, which may help to improve and maintain the safety and quality use of vaccines in immunization centers irrespective of the type of facility.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211032590"},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25151355211032590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39309834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnant women's hepatitis B vaccination coverage in Nigeria: a national pilot cross-sectional study.","authors":"George Uchenna Eleje, Godwin Otuodichinma Akaba, Ikechukwu Innocent Mbachu, Ayyuba Rabiu, Olabisi Morebise Loto, Hadiza Abdullahi Usman, Preye Owen Fiebai, Rebecca Chinyelu Chukwuanukwu, Ngozi Nneka Joe-Ikechebelu, Chike Henry Nwankwo, Stephen Okoroafor Kalu, Chinyere Ukamaka Onubogu, Chukwuanugo Nkemakonam Ogbuagu, Shirley Nneka Chukwurah, Chinwe Elizabeth Uzochukwu, Samuel Oluwagbenga Inuyomi, Bukola Abimbola Adesoji, Uchenna Chukwunonso Ogwaluonye, Sussan Ifeyinwa Nweje, Richard Obinwanne Egeonu, Odion Emmanuel Igue, Chiamaka Henrietta Jibuaku, Prince Ogbonnia Aja, Chiamaka Perpetua Chidozie, Hadiza Sani Ibrahim, Fatima Ele Aliyu, Aisha Ismaila Numan, Ogbonna Dennis Okoro, Solace Amechi Omoruyi, Ijeoma Chioma Oppah, Ubong Inyang Anyang, Aishat Ahmed, Osita Samuel Umeononihu, Eric Okechukwu Umeh, Ekene Agatha Emeka, Arinze Anthony Onwuegbuna, Emeka Philip Igbodike, Ifeoma Clara Ajuba, Ibrahim Adamu Yakasai, Oliver Chukwujekwu Ezechi, Joseph Ifeanyichukwu Ikechebelu","doi":"10.1177/25151355211032595","DOIUrl":"10.1177/25151355211032595","url":null,"abstract":"<p><strong>Objective: </strong>To determine the hepatitis B vaccination coverage, full-dose (⩾3) coverage and the associated factors affecting uptake among pregnant women.</p><p><strong>Methods: </strong>This was a cross-sectional study among pregnant women attending antenatal care in six tertiary hospitals across all the geopolitical zones of Nigeria. Pregnant women who consented to the study completed screening questions about their hepatitis B vaccination status and coverage. The main outcome measures were hepatitis B vaccination coverage rate, dose, and factors affecting uptake. Bivariate analysis was performed by the chi-square test and conditional logistic regression analysis was used to determine variables associated with uptake of the vaccination. Odds ratios (ORs) and adjusted odds ratios (aORs) were calculated and statistical significance was accepted when <i>p</i>-value was < 0.05.</p><p><strong>Results: </strong>Of 159 pregnant women who completed the interview questions, 21 [13.2%, 95% confidence interval (CI) 7.9-18.5%] were vaccinated for hepatitis B for one to three doses. The numbers of doses received were: three doses (8/159, 5.0%), two doses (5/159, 3.1%), and one dose (8/159, 5.0%). The reasons for non-uptake of vaccination included: lack of awareness of the vaccine 83/138 (60.1%), inadequate access to vaccine 11/138 (8.0%), and positivity to hepatitis B virus 10/138 (7.2%). The uptake of hepatitis B vaccination was significantly affected by the level of education (OR 0.284, 95% CI 0.08-1.01, <i>p</i> = 0.041), but in multivariable logistic regression, adjusted for confounders, the association between hepatitis B vaccination and participants' level of education (aOR 3.09; 95% CI 0.95-10.16; <i>p</i> = 0.061) did not remain significant.</p><p><strong>Conclusions: </strong>In Nigeria, the national hepatitis B vaccination coverage among pregnant women appears poor, with the full-dose coverage even poorer. The level of education was not positively associated with uptake of hepatitis B vaccination, while lack of awareness of the vaccine was the commonest reason for non-uptake.</p><p><strong>Funding: </strong>TETFund National Research Fund 2019 (grant number TETFund/DR&D/CE/NRF/STI/33).</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211032595"},"PeriodicalIF":0.0,"publicationDate":"2021-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/a3/10.1177_25151355211032595.PMC8327013.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39309836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generating CAR T cells from tumor-infiltrating lymphocytes.","authors":"Jane K Mills,&nbsp;Melissa A Henderson,&nbsp;Lauren Giuffrida,&nbsp;Pasquale Petrone,&nbsp;Jennifer A Westwood,&nbsp;Phillip K Darcy,&nbsp;Paul J Neeson,&nbsp;Michael H Kershaw,&nbsp;David E Gyorki","doi":"10.1177/25151355211017119","DOIUrl":"https://doi.org/10.1177/25151355211017119","url":null,"abstract":"<p><p><b>Background:</b> Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T-cell therapies have demonstrated promising, though limited, efficacy against melanoma. <b>Methods:</b> We designed a model system to explore the efficacy of dual specific T cells derived from melanoma patient TILs by transduction with a Her2-specific CAR. <b>Results:</b> Metastatic melanoma cells in our biobank constitutively expressed Her2 antigen. CAR-TIL produced greater amounts of IFN compared with parental TIL, when co-cultured with Her2 expressing tumor lines, including autologous melanoma tumor lines, although no consistent increase in cytotoxicity by TIL was afforded by expression of a CAR. Results of an <i>in vivo</i> study in NSG mice demonstrated tumor shrinkage when CAR-TILs were used in an adoptive cell therapy protocol. <b>Conclusion:</b> Potential limitations of transduced TIL in our study included limited proliferative potential and a terminally differentiated phenotype, which would need addressing in further work before consideration of clinical translation.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211017119"},"PeriodicalIF":0.0,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25151355211017119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39098380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it time to administer acellular pertussis vaccine to childbearing age/pregnant women in all areas using whole-cell pertussis vaccination schedule?","authors":"Abdoulreza Esteghamati,&nbsp;Shirin Sayyahfar,&nbsp;Yousef Alimohamadi,&nbsp;Sarvenaz Salahi,&nbsp;Mahmood Faramarzi","doi":"10.1177/25151355211015842","DOIUrl":"https://doi.org/10.1177/25151355211015842","url":null,"abstract":"<p><strong>Background: </strong>Whole-cell pertussis (wP) vaccine administration is still advocated for children under 7 years of age in Iran. However, there is no recommendation for the administration of a dose of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine to childbearing age/pregnant women in the Iranian vaccination program and it has increased the risk of infection through waning immunity during women's childbearing age life. The study aimed to assess the levels of anti-<i>Bordetella pertussis</i> antibodies in childbearing age women of different ages in Iran.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on a total number of 360 childbearing age women divided into six age groups, with 5-year intervals from 15 to 45 years old, in 2018-2019. Then, the levels of immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) antibodies against <i>B. pertussis</i> were evaluated using enzyme-linked immunosorbent assay (ELISA). The IBM SPSS Statistics software (version 16.0) (SPSS Inc., Chicago, IL, USA) was used for data analysis.</p><p><strong>Results: </strong>The mean age of the participants was 30.01 ± 8.35 years (range 14-45 years). All the cases were IgM negative, but two IgA-positive individuals (in the age groups of 14-19 and 30-34 years) were reported. Overall, 239 (66.4%) cases were IgG positive. The mean age of IgG-positive cases was 30.37 ± 8.37 years. The IgG-positive cases were mostly in the age groups of 30-34 and 35-39 years [43 (71.1%)]. The odds of IgG positivity were 1.97. The highest odds of IgG positivity were seen in 30-34 and 35-39 years groups (2.52) and the lowest odds were seen in the 20-24 and 25-29 years groups (1.60). Using the Jonckheere-Terpstra test, the increasing trend of IgG changes in different age groups was not statistically significant (Tπ=5.78, <i>p</i> = 0.09).</p><p><strong>Conclusion: </strong>The infants of women of childbearing age might be prone to pertussis in countries using the wP vaccination schedule. It is suggested to administer a dose of Tdap to women before or during pregnancy to increase the immunity of their infants against this disease during early infancy.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211015842"},"PeriodicalIF":0.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25151355211015842","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39093026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengvaxia: the world's first vaccine for prevention of secondary dengue.","authors":"Danielle Tully,&nbsp;Carrie L Griffiths","doi":"10.1177/25151355211015839","DOIUrl":"https://doi.org/10.1177/25151355211015839","url":null,"abstract":"<p><p>The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords 'dengue vaccine', 'Dengvaxia', 'efficacy' or 'safety'. Trials were selected if they appropriately assessed vaccine efficacy or were related to the vaccine approval process for CYD-TDV. Findings from this review underline the evolution of vaccine efficacy against seroprevalence, serotypes, and various ages. There are currently no preventive measures or antiviral treatments for dengue; CYD-TDV is the first vaccine to receive US Food and Drug Administration approval. Protective responses seen with the complete administration of CYD-TDV can become a standardized tool as part of a world vaccination program.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211015839"},"PeriodicalIF":0.0,"publicationDate":"2021-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25151355211015839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39032657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of indirect education on knowledge and perception on cervical cancer and its prevention among the parents of adolescent girls: an interventional school-based study.","authors":"Rony Abraham Jacob, Priya Srambical Abraham, Feba Rachel Thomas, Vytila Navya, Juny Sebastian, Mandyam Dhati Ravi, Parthasarathi Gurumurthy","doi":"10.1177/2515135521990268","DOIUrl":"10.1177/2515135521990268","url":null,"abstract":"<p><strong>Background: </strong>India has almost 225 million adolescent girls and they seem to be at a disadvantage, both economically and by their lack of knowledge on human papilloma virus (HPV) vaccine, when compared to adolescent girls of other Asian countries.</p><p><strong>Aim: </strong>To assess the prevalence of HPV vaccination and to identify the impact of education in improving the knowledge and perception about the HPV infection and vaccination among the parents of adolescent girls.</p><p><strong>Methodology: </strong>The prospective interventional study was conducted in four schools within a South Indian City, Mysuru. The informed consent form and the questionnaire were sent home with the identified adolescent girls during the pre-interventional phase. Educational sessions were conducted for the students in their school and an education leaflet was distributed to their parents. Three weeks later, questionnaires were re-administered to the parents <i>via</i> the enrolled girls and their responses were collected.</p><p><strong>Results: </strong>The prevalence of HPV vaccination in the study population was 4.4%. There was a statistically significant improvement in knowledge in the post-interventional phase of the study (<i>p</i> = 0.001), but could not identify a significant change in their perception (<i>p</i> = 0.479). Parents belonging to the socioeconomic class of upper middle and upper lower showed better improvement at the end of the study, with a percentage improvement of 58.93% and 48.44%, respectively.</p><p><strong>Conclusion: </strong>The study proved that the healt care professional can target school children to communicate effectively to their parents on the importance of HPV vaccine as the study clearly observed a positive behavioral change among the study population.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"2515135521990268"},"PeriodicalIF":0.0,"publicationDate":"2021-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/14/10.1177_2515135521990268.PMC7882753.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for active and passive pediatric RSV immunization.","authors":"Katherine M Eichinger, Jessica L Kosanovich, Madeline Lipp, Kerry M Empey, Nikolai Petrovsky","doi":"10.1177/2515135520981516","DOIUrl":"10.1177/2515135520981516","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children worldwide, with the most severe disease occurring in very young infants. Despite half a century of research there still are no licensed RSV vaccines. Difficulties in RSV vaccine development stem from a number of factors, including: (a) a very short time frame between birth and first RSV exposure; (b) interfering effects of maternal antibodies; and (c) differentially regulated immune responses in infants causing a marked T helper 2 (Th2) immune bias. This review seeks to provide an age-specific understanding of RSV immunity critical to the development of a successful pediatric RSV vaccine. Historical and future approaches to the prevention of infant RSV are reviewed, including passive protection using monoclonal antibodies or maternal immunization strategies versus active infant immunization using pre-fusion forms of RSV F protein antigens formulated with novel adjuvants such as Advax that avoid excess Th2 immune polarization.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"2515135520981516"},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/0e/10.1177_2515135520981516.PMC7879001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25399266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The digital immunization system of the future: imagining a patient-centric, interoperable immunization information system.","authors":"Katherine M Atkinson, Salima Saleem Mithani, Cameron Bell, Taylor Rubens-Augustson, Kumanan Wilson","doi":"10.1177/2515135520967203","DOIUrl":"10.1177/2515135520967203","url":null,"abstract":"<p><p>To ensure the effectiveness of increasingly complex immunization programs in upper-middle and high-income settings, comprehensive information systems are needed to track immunization uptake at individual and population levels. The maturity of cloud systems and mobile technologies has created new possibilities for immunization information systems. In this paper, we describe a vision for the next generation of digital immunization information systems for upper-middle and high-income settings based on our experience in Canada. These systems center on the premise that the public is engaged and informed about the immunization process beyond their interaction with primary care, and that they will be a contributor and auditor of immunization data. The digital immunization system of the future will facilitate reporting of adverse events following immunization, issue digital immunization receipts, permit identification of areas of need and allow for delivery of interventions targeting these areas. Through features like immunization reminders and targeted immunization promotion campaigns, the system will reduce many of the known barriers that influence immunization rates. In light of the global COVID-19 pandemic, adaptive digital public health information systems will be required to guide the rollout and post-market surveillance of the SARS-CoV-2 vaccine.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"8 ","pages":"2515135520967203"},"PeriodicalIF":0.0,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/27/10.1177_2515135520967203.PMC7900792.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25446414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}